Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07560579 · ClinicalTrials.gov registry record · NA
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
A NA study, sponsored by Million Marker Wellness.
- Active
- Registry status
- NA
- Development phase
- 226
- Enrollment target
NCT07560579: Active NA study, sponsored by Million Marker Wellness.
NCT07560579 is a NA study that is active but no longer recruiting, run by Million Marker Wellness. The registered enrollment target is 226 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07560579, a NA study, is active but no longer recruiting, sponsored by Million Marker Wellness.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 226 participants
- Enrollment target
Study Summary
The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial. The main questions this study aims to answer are: 1. If MM's 12-week EDC intervention program (EDC testing and report-back, EDC reduction curriculum) can reduce weight? 2. If a 12-week validated digital weight loss program can reduce EDC exposures? 3. What is the effectiveness of the two interventions at reducing weight and urinary EDC metabolites? Participants will be assigned to one of these two arms. Participants will collect their urine and blood samples pre- and post-intervention, and will take a comprehensive exposure survey before sending back their samples. This exposure survey will ask about participant's weight loss literacy, environmental health literacy, product use, diet, and lifestyle behaviors.
Primary Outcome
EDC intervention that reduces EDC exposure also help individuals to lose weight. Comparing the two interventions to see which is more effective (EDC intervention or traditional weight loss intervention).
Interventions
- DIAGNOSTIC_TEST Urinary EDC metabolite testing
- BEHAVIORAL Educational curriculum
- BEHAVIORAL Weight loss Application
- DIAGNOSTIC_TEST Siphox clinic biomarker test
- DIAGNOSTIC_TEST Weight loss reporting
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT07560579 still lists
NCT07560579 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 5 interventions - of which Urinary EDC metabolite testing is the first listed.
NCT07560579 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07560579 about?
NCT07560579 is a clinical study titled "Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity". The goal of this study is to examine the relationship in individuals with overweight/obesity and endocrine disrupting chemical (EDC) exposure through a two-armed, randomized clinical trial. The main questions this study aims to answer are: 1. If MM's 12-week EDC intervention program (EDC testing an...
What is the current status of trial NCT07560579?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 226 participants. The study started on 2025-08-18. Estimated completion is 2026-09.
What interventions are being tested in trial NCT07560579?
The interventions under investigation include: Urinary EDC metabolite testing (DIAGNOSTIC_TEST), Educational curriculum (BEHAVIORAL), Weight loss Application (BEHAVIORAL), Siphox clinic biomarker test (DIAGNOSTIC_TEST), Weight loss reporting (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07560579?
This trial is sponsored by Million Marker Wellness, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07560579's enrollment target sits among peer trials
226 471st of 2000 higher than 1,529 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI